Philips—Philips Respironics recalled 15 million sleep-apnea and ventilator devices over toxic foam risk, leading to $1.1B settlement and FDA consent decree
In June 2021, Philips Respironics recalled roughly 15 million CPAP, BiPAP, and mechanical ventilator devices worldwide after discovering that sound-abatement foam inside the machines could degrade and release toxic particles and gases that users could inhale or ingest. The recall triggered mass litigation (MDL 3014) consolidated in the Western District of Pennsylvania, resulting in a $479 million economic-loss settlement (September 2023) and a $1.1 billion personal-injury/medical-monitoring settlement (March 2024), both reached without Philips admitting fault or liability. In 2024, a US federal court entered a consent decree against Philips Respironics and named Royal Philips CEO Roy Jakobs as a defendant, restricting the company's production and sale of new devices at its Pennsylvania and California facilities until FDA compliance requirements are met.
Scoring Impact
| Topic | Direction | Relevance | Contribution |
|---|---|---|---|
| Consumer Protection | -against | primary | -1.00 |
| Overall incident score = | -1.324 | ||
Score = avg(topic contributions) × significance (critical ×2) × confidence (0.66)
Evidence (2 signals)
NYT: Philips settles CPAP breathing device lawsuits for $1.1 billion
The New York Times reported Philips agreed to pay $1.1 billion to settle personal-injury and medical-monitoring claims from users of its recalled CPAP and BiPAP breathing devices, without admitting fault, following the June 2021 recall of millions of machines over toxic foam degradation risk.
FDA: federal court enters consent decree against Philips Respironics following sleep-apnea device recall
The FDA announced that a US federal court entered a consent decree against Philips Respironics, Respironics California, Philips Holding USA, and Royal Philips CEO Roy Jakobs, restricting production and sale of new CPAP/BiPAP devices at Pennsylvania and California facilities until the company meets FDA compliance requirements stemming from the 2021 recall of roughly 15 million devices.